Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of HelloFresh SE regarding potential securities fraud and unlawful business practices by the company and its executives [1]. Group 1: Allegations and Investigations - Grizzly Research published a report on November 6, 2025, alleging that HelloFresh's business is in sharp decline, with management prioritizing self-enrichment over shareholder interests [2]. - The report claims that customer demand has decreased, while the CEO has extracted cash by using HelloFresh shares as collateral for personal bank loans related to real estate investments managed by his brother [2]. Group 2: Market Reaction - Following the publication of the report, HelloFresh's stock price fell by $0.11 per share, or 6.3%, closing at $1.65 per share on November 6, 2025 [3].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc regarding potential securities fraud or unlawful business practices [1] - RBC Capital Markets analyst downgraded Bicycle to Sector Perform from Outperform due to delays in the development of zelenectide pevedotin for metastatic urothelial cancer, which is now pushed to the first quarter of 2026 [2] - Following the downgrade, Bicycle's ADR price fell by $0.69, or 7.88%, closing at $8.07 on October 31, 2025 [3] Company Developments - The investigation by Pomerantz LLP focuses on whether Bicycle and its officers/directors have engaged in any fraudulent activities [1] - The delay in the development of zelenectide pevedotin is significant as the urothelial cancer treatment market is becoming increasingly competitive, with potential advantages for competing products, particularly from Pfizer [2] - The recent downgrade and subsequent price drop indicate investor concerns regarding Bicycle's market position and product development timeline [3]

Core Viewpoint - Logitech International S.A. is under investigation for potential securities fraud and unlawful business practices following a cybersecurity incident that led to data exfiltration [1][2]. Group 1: Cybersecurity Incident - On November 14, 2025, Logitech announced a cybersecurity incident involving the exfiltration of data, believed to have been executed through a zero-day vulnerability in third-party software [2]. - The data compromised likely included limited information about employees, consumers, customers, and suppliers [2]. - Following the announcement, Logitech's stock price dropped by $4.75 per share, or 4.02%, closing at $113.27 on November 17, 2025 [2]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Logitech investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving StubHub Holdings, Inc. following its recent IPO and subsequent stock price declines due to financial reporting and regulatory scrutiny [1][2]. Financial Performance - StubHub conducted its IPO on September 17, 2025, offering 34,042,553 shares at a price of $23.50 per share [2]. - In its third-quarter financial results reported on September 13, 2025, StubHub exceeded revenue expectations but did not provide a forecast for the current quarter, leading to analyst downgrades [2]. - Following the lack of guidance, StubHub's stock price dropped by $3.95, or 20.99%, closing at $14.87 on November 14, 2025 [2]. Regulatory Issues - On November 17, 2025, the UK's Competition and Markets Authority announced an investigation into StubHub's compliance with consumer protection laws, particularly regarding online pricing practices [2]. - This regulatory news caused StubHub's stock to decline further by $0.76, or 5.93%, closing at $12.06 on November 18, 2025 [2].

Core Viewpoint - Home Depot's recent financial results for Q3 2025 fell short of forecasts, leading to a significant drop in stock price, attributed to a lack of storms and consumer uncertainty impacting demand [2]. Financial Performance - Home Depot reported earnings per share and sales that missed forecasts, primarily due to the lack of storms in Q3 2025, which resulted in greater than expected pressure in certain categories [2]. - The company projected same-store sales for the full year to be "slightly positive," a downgrade from the previous expectation of a 1% increase [2]. - Adjusted earnings per share are forecasted to drop by 5%, exceeding the previously projected 2% decline [2]. - Following the announcement, Home Depot's stock price fell by $21.55 per share, or 6.02%, closing at $336.48 per share on November 18, 2025 [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or unlawful business practices by Home Depot and its officers/directors [1].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Plug Power Inc. following the company's suspension of plans to build hydrogen production facilities, which jeopardizes a significant federal loan guarantee [1][2]. Group 1: Company Actions - On November 13, 2025, Plug Power announced the suspension of plans to construct six facilities for producing and liquefying zero or low-carbon hydrogen, which puts at risk a $1.66 billion federal loan guarantee obtained in January [2]. - Following this announcement, Plug's stock price decreased by $0.48 per share, representing a 17.58% decline, closing at $2.25 per share on November 14, 2025 [2]. Group 2: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of Plug Power investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving uniQure N.V. and its officers or directors [1] - uniQure announced feedback from the FDA indicating that data from Phase I/II studies of its investigational gene therapy AMT-130 may not be sufficient for a Biologics License Application (BLA) submission, leading to a significant drop in stock price [2] Group 1: Company Developments - On November 3, 2025, uniQure received feedback from the FDA during a pre-BLA meeting regarding AMT-130, a gene therapy for Huntington's disease [2] - The FDA's feedback represents a key shift from previous communications, causing uncertainty about the timing of the BLA submission for AMT-130 [2] - Following the announcement, uniQure's stock price fell by $33.40, or 49.34%, closing at $34.29 per share [2] Group 2: Legal Investigations - Pomerantz LLP is actively investigating claims on behalf of investors of uniQure regarding potential securities fraud [1] - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3]

Core Insights - Alkami Technology, Inc. is under investigation for potential securities fraud and unlawful business practices [1] - The company reported third-quarter 2025 financial results, with GAAP earnings per share of -$0.14, missing estimates by $0.02, and revenue of $113 million, missing estimates by $0.48 million [2] - Following the earnings report, Alkami's stock price dropped by $1.70, or 7.73%, closing at $20.29 per share [2] Company Financial Performance - For Q3 2025, Alkami reported a GAAP earnings per share of -$0.14, which was below the consensus estimate by $0.02 [2] - The revenue for the same quarter was $113 million, falling short of consensus estimates by $0.48 million [2] Stock Market Reaction - The announcement of the financial results led to a decline in Alkami's stock price by $1.70, representing a 7.73% decrease [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Regencell Bioscience Holdings Limited and its officers or directors [1][2]. Group 1: Investigation Details - Regencell disclosed on October 31, 2025, that it received a subpoena from the U.S. Department of Justice (DOJ) regarding an investigation into trading of its Ordinary Shares [2]. - The DOJ has requested documents and communications related to corporate operational, financial, and accounting matters [2]. - Regencell anticipates incurring significant legal costs and may face fines or penalties exceeding its insurance coverage due to the investigation [2]. Group 2: Market Reaction - Following the announcement of the DOJ investigation, Regencell's stock price dropped by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Beyond Meat, Inc. and its officers or directors, following significant stock price declines related to impairment charges and delayed earnings announcements [1][2]. Group 1: Company Financial Issues - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to long-lived assets, which was anticipated to be material [2]. - Following this announcement, Beyond Meat's stock price dropped by $0.655 per share, or 23.06%, closing at $2.185 per share on the same day [2]. - On November 3, 2025, the company delayed its third-quarter earnings announcement, citing the need for additional time to complete the impairment review, resulting in a further stock price decline of $0.275 per share, or 16.52%, closing at $1.39 per share [2]. Group 2: Legal Investigation - Pomerantz LLP, a firm recognized for its work in corporate and securities class litigation, is leading the investigation into Beyond Meat's practices, emphasizing its long history of fighting for victims of securities fraud and corporate misconduct [3].